HER2 Low Breast Cancer A New Therapeutic Subtype | 2023 KU Breast Cancer Year in Review Conference Total Health | Oncology 25:20 1 year ago 2 144 Скачать Далее
DESTINY-Breast04: practice-changing results for HER2-low breast cancer VJOncology 2:01 2 years ago 1 324 Скачать Далее
The Science of HER2-low Breast Cancer and Implications for the Pathology Team ASCP 54:43 2 years ago 2 703 Скачать Далее
Advances in novel ADCs for HER2-expressing breast cancer VJOncology 1:35 1 year ago 222 Скачать Далее
A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer PeerView Oncology 1:25:22 1 year ago 2 273 Скачать Далее
Novel antibody-drug conjugates (ADCs) technologies for management of mBC ecancer 10:21 1 year ago 90 Скачать Далее
Antibody-Drug Conjugates for HER2-Low Disease: 2023 KU Breast Cancer Year in Review Total Health | Oncology 2:06 1 year ago 92 Скачать Далее
Clinical outcomes in women with metastatic HER2-low breast cancer in the real world VJOncology 1:17 2 years ago 191 Скачать Далее
Treatment Options for HER2-Low Breast Cancer: All You Need to Know Yerbba – Breast Cancer 5:16 6 months ago 2 787 Скачать Далее
Remaining questions surrounding HER2-low breast cancer – how low can you go? VJOncology 2:13 1 year ago 311 Скачать Далее
Trastuzumab deruxtecan: a promising agent for treating HER2-low breast cancer? VJOncology 4:01 3 years ago 1 486 Скачать Далее
The evolution of HER2-low breast cancer from primary to recurrence VJOncology 0:45 1 year ago 159 Скачать Далее
Remaining questions on the management of HER2-low breast cancer VJOncology 0:56 1 year ago 156 Скачать Далее
